ACTRN12613000627752Not yet recruiting未知
Efficacy and safety of the fixed combinations of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in sentinel sites of Melen (Estuary) and of Franceville (Haut Ogooue) in Gabon
PNLP Ministere de la Sante GABO0 sites288 target enrollmentStarted: May 31, 2013Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 288
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 1 Years to 12 Years (—)
- Sex
- All
Inclusion Criteria
- •Axillary temperature equal or greater than 37.5 degrees Celsius or history of fever in the past 24 hours.
- •Parasitemia, asexual forms between 2000 and 200 000 per microliter of blood.
- •Mono-infection with plasmodium falciparum confirmed by microscopy.
- •Age between 12 months and 12 years.
- •Body weight greater than 5 kg.
- •Absence of clinical signs of severe malaria
- •Absence of known serious chronic disease.
- •Absence of severe malnutrition.
- •Capacity to swallow oral medication.
- •Capable and willing to follow protocol requirement including schedule of assessments
- •Consent from parent or guardian.
- •Assent from children aged 11 and 12 years.
Exclusion Criteria
- •Presence of general danger signs in children aged under 5 years, or signs of severe falciparum malaria according to WHO definition.
- •Mixed or mono-infection with another Plasmodium species detected by microscopy.
- •Presence of severe malnutrition (defined as a child whose growth standard is below minus 3z-score, has symmetrical oedema involving at least the feet, or has mid-upper arm circumference less than 110 mm.
- •Presence of febrile conditions due to diseases other than malaria (measles, acute lowest respiratory tract infection, severe dirrhoea with dehydration) or other known underlyning chronic diseases (cardiac, renal and hepatic diseases, HIV/AIDS).
- •Regular medication, which may interfere with animalarial pharmacokinetics;
- •History of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatments
- •Likehood of pre-pubescence or pubescence in female.
- •Refusal to consent.
- •Not capable to comply with visit schedule.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Evaluation of the tolerance and efficacy of T2347 in patients with glaucoma or ocular hypertension, stabilized with Xalacom® or genericsglaucoma, ocular hypertensionMedDRA version: 17.0 Level: HLGT Classification code 10018307 Term: Glaucoma and ocular hypertension System Organ Class: 10015919 - Eye disordersEUCTR2013-005222-29-GBaboratoires THÉA210
Active, not recruiting
Not Applicable
Evaluation of the tolerance and efficacy of T2347 in patients with glaucoma or ocular hypertension, stabilized with Xalacom® or genericsglaucoma, ocular hypertensionMedDRA version: 17.0Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2013-005222-29-BEaboratoires THÉA210
Active, not recruiting
Phase 1
Evaluation of the tolerance and efficacy of T2347 in patients with glaucoma or ocular hypertension, stabilized with Xalacom® or genericsEUCTR2013-005222-29-DEaboratoires THÉA210
Active, not recruiting
Not Applicable
Evaluation of the tolerance and efficacy of T2347 in patients with glaucoma or ocular hypertension, stabilized with Xalacom® or genericsglaucoma, ocular hypertensionEUCTR2013-005222-29-LVaboratoires THÉA210
Active, not recruiting
Not Applicable
Evaluation of the tolerance and efficacy of T2347 in patients with glaucoma or ocular hypertension, stabilized with Xalacom® or genericsglaucoma, ocular hypertensionMedDRA version: 17.1Level: HLGTClassification code 10018307Term: Glaucoma and ocular hypertensionSystem Organ Class: 10015919 - Eye disordersEUCTR2013-005222-29-HUaboratoires THÉA210